How Do I Find Mesothelioma Treatment Near Me?
If you’ve been diagnosed with mesothelioma, you and your family may be wondering where you can get the best treatment. Fortunately, there are many cancer centers across the country with doctors who specialize in mesothelioma. These doctors can develop a custom treatment plan based on your individual needs and diagnosis.
Your treatment plan may include a combination of chemotherapy, surgery, and other therapies. You may also be able to access new treatments through clinical trials.
The first step to receiving the right treatment is to make an appointment with a mesothelioma doctor.
Connect with mesothelioma specialists near you with our Free Doctor Match service.
Top States for Mesothelioma Treatment
From Moffitt Cancer Center in Tampa to UCLA Medical Center in Los Angeles, there are a number of mesothelioma treatment centers across the country that can provide patients with specialized cancer care.
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- Washington DC
- West Virginia
- Wisconsin
- Wyoming
If you or a loved one is researching mesothelioma cancer centers, try looking for hospitals that have been recognized by the National Cancer Institute (NCI). This indicates that the facility has met strict criteria for conducting advanced cancer research aimed at finding better ways to prevent, diagnose, and treat mesothelioma.
All of the states listed above are home to at least one NCI-designated cancer center.
Mesothelioma Treatment Options
Pursuing treatment at a mesothelioma center is critical to improving your overall prognosis and life expectancy.
Pleural mesothelioma patients who receive standard treatments have higher survival rates than patients who go untreated, according to a 2023 report in Cancer Medicine.
Standard mesothelioma treatment options include:
- Surgery: Malignant mesothelioma patients may be eligible for tumor-removing surgeries as well as minor outpatient procedures that can help relieve swelling, chest pain, and other painful symptoms.
- Chemotherapy: Powerful chemotherapy medications are administered orally or intravenously to target and kill mesothelioma cancer cells throughout the body.
- Immunotherapy: Various types of immunotherapy drugs strengthen the immune system’s ability to target and destroy cancer cells.
- Radiation therapy: High-energy radiation is delivered directly to areas with mesothelioma tumors, destroying cancer cells while minimizing damage to healthy tissues.
- Palliative care: Patients can receive palliative care alongside standard treatments to manage pain, reduce symptoms, and provide emotional support.
A clinical trial led by researchers at MD Anderson Cancer Center found that 40% of peritoneal mesothelioma patients achieved complete or partial remission after being treated with the immunotherapy medications atezolizumab (TECENTRIQ®) and bevacizumab (Avastin®).
Locate Mesothelioma Clinical Trials Near You
Clinical trials for mesothelioma are available in some states. Mesothelioma Hope maintains an up-to-date list of ongoing clinical trials categorized by location.
Use our search tool below to see if there are any active mesothelioma clinical trials in your area and get help enrolling.
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
- Mesothelioma, Malignant
- Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- University of Kansas Cancer Center, Westwood, Kansas
- University of Pennsylvania, Philadelphia, Pennsylvania
- MD Anderson Cancer Center, Houston, Texas
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
- Pleural Biphasic Mesothelioma
- Biological: Nivolumab
- Biological: Ipilimumab
- Procedure: Surgical Procedure
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska
- Anchorage Radiation Therapy Center, Anchorage, Alaska
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska
- Alaska Oncology and Hematology LLC, Anchorage, Alaska
- Alaska Women's Cancer Care, Anchorage, Alaska
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
- Drug: KFA115
- Massachusetts General Hospital ., Boston, Massachusetts
- Massachusetts General Hospital, Boston, Massachusetts
- NYU School of Medicine, New York, New York
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- SCRI Oncology Partners, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma; Pleura
- Drug: Sacituzumab govitecan-hziy
- Memorial Sloan - Kettering Cancer Center, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
- Mesothelioma
- Drug: Magnesium sulfate
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Integrated Cancer Repository for Cancer Research
- Lung Cancer
- Advent Health, Greenwood Village, Colorado
- Florida Hospital Memorial Medical Center, Daytona Beach, Florida
- Florida Hospital DeLand, DeLand, Florida
- Florida Hospital FISH, Orange City, Florida
- Florida Hospital Flagler, Palm Coast, Florida
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
- The University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma
- Mesothelioma
- Drug: Durvalumab / tremelimumab
- Duke Cancer Institute, Durham, North Carolina
- Baylor St Lukes, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Peritoneal Malignant Mesothelioma
- Biological: Atezolizumab
- Biological: Bevacizumab
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Procedure: Computed Tomography
- Procedure: Cytoreductive Surgery
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Carle at The Riverfront, Danville, Illinois
- Carle Physician Group-Effingham, Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations
- Mesothelioma, Malignant
- Drug: SW-682
- SpringWorks Clinical Trial Site, Scottsdale, Arizona
- UC San Diego Moores Cancer Center, La Jolla, California
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- SpringWorks Clinical Trial Site, Los Angeles, California
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
- Lung Cancer
- Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
- Providence Medical Foundation (site 209), Santa Rosa, California
- Hartford Hospital (site 210), Hartford, Connecticut
- The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia
- Holy Cross Hospital (site 213), Fort Lauderdale, Florida
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Pembroke Pines, Florida
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- Mesothelioma
- Drug: NXP900
- Mayo Clinic, Phoenix, Arizona
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado
- Mayo Clinic, Jacksonville, Florida
- Oregon Health and Science University, Portland, Oregon
- The University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
- Drug: HFB200301
- Mayo Clinic, Scottsdale, Arizona
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- Mayo Clinic, Jacksonville, Florida
- Mayo Clinic, Rochester, Minnesota
- Washington University School of Medicine, St Louis, Missouri
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
- Drug: CAR.70/IL15-transduced CB-derived NK cells
- Drug: Fludarabine phosphate
- Drug: Cyclophosphamide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
- Malignant Mesothelioma
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- BAP1 Gene Mutation
- Mesothelioma
- The Ohio State University Wexner Medical Center, Columbus, Ohio
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated With an Adoptive Cellular Therapy
- Mesothelioma
- Lung Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Drug: CT-95
- Context Investigational Site, Denver, Colorado
- Context Investigational Site, Chicago, Illinois
- Context Investigational Site, Grand Rapids, Michigan
- Context Investigational Site, Hackensack, New Jersey
- Context Investigational Site, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
- Mesothelioma
- Drug: BGC515
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
- Malignant Pleural Mesothelioma
- Biological: CTX131
- Research Site 3, Duarte, California
- Research Site 7, Chicago, Illinois
- Research Site 6, Boston, Massachusetts
- Research Site 2, St Louis, Missouri
- Research Site 4, Durham, North Carolina
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- Mesothelioma
- Device: mesothelin expression testing
- Biological: TNhYP217 CAR T Cells
- Drug: fludarabine
- Drug: cyclophosphamide
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
- Peritoneal Mesothelioma
- Mesothelioma
- Mesothelioma, Malignant
- Malignant Mesothelioma
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
- University of Chicago (Data Collection Only), Chicago, Illinois
- University of Michigan (Data Collection Only), Ann Arbor, Michigan
- Washington University (Data Collection Only), St Louis, Missouri
- University of Nebraska (Data collection only), Omaha, Nebraska
- Rutgers University (Data Collection Only), New Brunswick, New Jersey
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)
- Drug: Volrustomig
- Drug: Pemetrexed
- Drug: Carboplatin
- Research Site, Phoenix, Arizona
- Research Site, Duarte, California
- Research Site, Santa Rosa, California
- Research Site, Aurora, Colorado
- Research Site, Jacksonville, Florida
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies
- Malignant Pleural Mesotheliomas NOS
- Lung Cancer NOS
- Thoracic Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Mesothelioma, Malignant
- Drug: Tulmimetostat
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- University of Chicago Medical Center, Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
- Mesothelioma
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- Drug: Fludarabine + Cyclophosphamide combination
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Mesotheliomas Pleural
- Drug: Pembrolizumab
- Procedure: Indocyanine Green (ICG) Image-Guided Surgery
- Drug: Cisplatin
- Drug: Pemetrexed
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- Peritoneal Carcinomatosis
- Peritoneal Mesothelioma
- Procedure: Heated Intraperitonial Chemotherapy
- Drug: Oxaliplatin
- Drug: 5-Fluorouracil
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive
- Drug: [203Pb]Pb-PSV359
- Drug: [212Pb]Pb-PSV359
- Saint Louis University, St Louis, Missouri
- Nebraska Cancer Specialists, Omaha, Nebraska
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Drug: TNG462
- Drug: Pembrolizumab
- Stanford University, Palo Alto, California
- Grand Valley Oncology, Grand Junction, Colorado
- Florida Cancer Specialists & Research Institute, Lake Mary, Florida
- Sylvester Comprehensive Cancer Center, Miami, Florida
- University Chicago Medicine, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
- Mesothelioma
- Drug: Olaparib
- University of Chicago Medical Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Pleural Effusion, Malignant
- Ascites, Malignant
- xCures, Oakland, California
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
- Recurrent Malignant Mesothelioma
- Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Drug: Cyclophosphamide
- Drug: Etoposide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
- Malignant Pleural Mesothelioma
- Diagnostic Test: E-Nose testing
- Diagnostic Test: Research blood
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Pembrolizumab
- Radiation: IMPRINT
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- Mesothelioma
- Drug: [18F]FAPI-74
- Drug: [18F]FDG
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
- Mesothelioma
- Drug: PF-08052666
- University of Alabama at Birmingham, Birmingham, Alabama
- The University of Alabama at Birmingham, Birmingham, Alabama
- University of Alabama at Birmingham, Birmingham, Alabama
- The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Birmingham, Alabama
- Mayo Clinic Hospital, Phoenix, Arizona
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Drug: VET3-TGI
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- UC Irvine Health, Orange, California
- University of Miami, Miami, Florida
- Community Health Network, Indianapolis, Indiana
- UPMC- Hillman Cancer Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- Drug: NX-1607
- City of Hope, Duarte, California
- University of Southern California, Los Angeles, California
- University of California, San Francisco, San Francisco, California
- University of Colorado School of Medicine, Aurora, Colorado
- University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
- Non Small Cell Lung Cancer
- Banner Health, Gilbert, Arizona
- Mayo Clinic Hospital, Phoenix, Arizona
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- Stanford University, Palo Alto, California
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: AG-01 Compound
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Drug: MDNA11
- Drug: Pembrolizumab (KEYTRUDA®)
- Sharp Memorial Hospital, San Diego, California
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
- Providence Saint John's Health Center, Santa Monica, California
- Boca Raton Regional Hospital, Boca Raton, Florida
- Emory - Winship Cancer Institute, Atlanta, Georgia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
- Pleural Mesothelioma
- Drug: Alintegimod
- Drug: Ipilimumab
- Drug: Nivolumab
- Florida Cancer Specialists, Lake Mary, Florida
- Dartmouth Hitchcock, Lebanon, New Hampshire
- Brown University Health Cancer Institute, Providence, Rhode Island
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Non Small Cell Lung Cancer
- Biological: A2B694
- Diagnostic Test: xT CDx with HLA-LOH Assay
- Banner Health, Gilbert, Arizona
- UCSD Moores Cancer Center, La Jolla, California
- UCLA Medical Center, Los Angeles, California
- Stanford University, Stanford, California
- Mayo Clinic, Jacksonville, Florida
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
- Malignant Mesothelioma
- Drug: ISM6331
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
- University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania
- SCRI Oncology Partners, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: MRTX1719
- Mayo Clinic, Phoenix, Arizona
- Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado
- Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado
- Mayo Clinic, Jacksonville, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
- Lung Cancer
- Radiation: MR-guided Linac
- Brigham & Women's Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
- Primary Peritoneal Carcinoma
- Non-small Cell Lung Cancer
- Drug: Rina-S
- USOR HonorHealth, Phoenix, Arizona
- USOR Arizona Oncology Associates, Tucson, Arizona
- University of California Los Angeles Medical Center, Los Angeles, California
- University of California, San Diego; Moores Cancer Center, San Diego, California
- USOR Sansum Clinic, Santa Barbara, California
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
- Mesothelioma
- Drug: VT3989
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Clinical Utility of Portable Dynamic Chest X-Ray (DDR) in the ICU: Clinical Trial to Demonstrate the Feasibility of Deploying DDR Technology in the ICU - A Study to Prove Its Increased Diagnostic Value
- Diagnostic Test: Portable Dynamic Digital Radiography (DDR)
- Brigham and Women's Hospital, Boston, Massachusetts
What State Has the Highest Rate of Mesothelioma?
California ranks first among states with the most mesothelioma cases. A total of 6,503 Californians were diagnosed with mesothelioma between 1999 and 2018, according to the Centers for Disease Control and Prevention (CDC).
Mesothelioma Rates by State
Some states have higher rates of mesothelioma because they have a long history of industries that heavily relied on asbestos, such as shipbuilding, mining, and manufacturing.
According to CDC data, these 10 states have the highest incidence rates for mesothelioma:
| State | Mesothelioma Cases | Population | Incidence Rate |
|---|---|---|---|
| 1. Maine | 513 | 1,340,123 | 1.5% |
| 2. Alaska | 128 | 736,624 | 1.4% |
| 3. New Jersey | 2,654 | 8,891,730 | 1.4% |
| 4. Delaware | 272 | 966,985 | 1.4% |
| 5. Washington | 1,799 | 7,526,793 | 1.3% |
| 6. Louisiana | 1,228 | 46,000,000 | 1.3% |
| 7. West Virginia | 614 | 1,805,953 | 1.3% |
| 8. Wyoming | 147 | 579,054 | 1.3% |
| 9. Pennsylvania | 4,040 | 12,807,060 | 1.3% |
| 10. Wisconsin | 1,581 | 5,809,319 | 1.3% |
Thankfully, there are experienced specialists in each of these states who can treat people diagnosed with mesothelioma and other asbestos-related diseases.
Learn more about treatments, specialists, and help for asbestos exposure in our Free Mesothelioma Guide — shipped overnight to your door.
Find Mesothelioma Treatment Near You Today
Locating mesothelioma treatment near you is a crucial step you can take toward fighting this rare cancer. With advancements in mesothelioma research and treatment options, there is increasing hope for better survival outcomes and improved quality of life.
Our highly trained Patient Advocates can help you connect with mesothelioma doctors and treatment centers in your state. We can also see if you qualify for financial assistance that can help pay for your cancer treatments.
Give us a call at (866) 608-8933 or use our Free Doctor Match service to get started.



